Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2263 • ACR Convergence 2025
Comparison of a Patient-Reported Disease Activity Measure with Physician-Based Indices in Rheumatoid Arthritis Patients in Nigeria
Uchechukwu Tralagba¹, Courage Uhunmwangho², Olufemi Adelowo³, Henry Nwankwo⁴, Dasetima Altraide¹, Ejiehi Aigbokhan⁵, Ako Itam⁶, Omokhowa Asekhame⁴ and Hakeem Olaosebikan³, ¹University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers, Nigeria, ²Jos University Teaching Hospital, Jos, Plateau, Nigeria, ³Lagos state university teaching hospital, Ikeja, Lagos, Nigeria, ⁴Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra, Nigeria, ⁵University of Benin Teaching Hospital, Benin, Edo, Nigeria, ⁶University of Calabar Teaching Hospital, Calabar, Cross River, Nigeria
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of synovial joints with extra articular manifestations. Disease activity indices in Rheumatoid…
Abstract Number: 2246 • ACR Convergence 2025
Different Populations, Different SDAI Cut-Off? A Proposal for a New Remission Threshold in Brazilian RA Patients from a National Multicenter Study
Lucas Pires¹, Alisson Pugliesi¹, Cleandro Pires², Ana Carolina Hidaka³, Vitor Cruz⁴, Manoel Barros Bertolo¹, Ana Paula Reis⁵, Rina Dalva Neubarth Giorgi⁶, Leticia Pereira⁷, Sebastião Cezar Radominski⁸, Ivanio Alves Pereira⁹, Maria Fernanda Brandão de Resende Guimarães¹⁰, Paulo Louzada Junior¹¹, Maria de Fátima Lobato da Cunha Sauma¹², Karina Bonfiglioli¹³, Claiton Viegas Brenol¹⁴, Licia Maria Henrique da Mota² and Geraldo da Rocha Castelar Pinheiro⁷, ¹Unicamp, Campinas, Brazil, ²UNB, Brasilia, Distrito Federal, Brazil, ³UNB, Brasilia, Brazil, ⁴UFG, Goias, Brazil, ⁵UniCEUB, Brasilia, Brazil, ⁶IAMSPE, São Paulo, Brazil, ⁷UERJ, Rio de Janeiro, Brazil, ⁸UFPR, Curitiba, Brazil, ⁹UFSC, Florianopolis, Brazil, ¹⁰UFMG, Belo Horizonte, Brazil, ¹¹USP-RP, Ribeirão Preto, Brazil, ¹²UFPA, Belem, Brazil, ¹³USP-SP, São Paulo, Brazil, ¹⁴UFRGS, Porto Alegre, Brazil
Background/Purpose: Remission criteria in Rheumatoid Arthritis (RA) have continuously evolved to balance the risks of both overtreatment and undertreatment. The most recent update includes the…
Abstract Number: 2229 • ACR Convergence 2025
National Multicenter study of Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease: effectiveness and progressive lung disease
Ana Serrano-Combarro¹, Belén Atienza-mateo², Jesús Loarce³, César Antonio Egües Dubuc⁴, Marta Pastor Mena⁵, Rafael B. Melero-González⁶, Sara Maria Rojas Herrera⁷, Carmen Carrasco-Cubero⁸, Carolina Perez Garcia⁹, Juan María Blanco-Madrigal¹⁰, Nuria Vegas Revenga¹¹, Deseada Palma-Sanchez¹², Andrea García-Valle¹³, Virginia Ruiz-Esquide¹⁴, Jose Ramón Lamua-Riazuelo¹⁵, Santos Castañeda¹⁶ and Ricardo Blanco¹⁷, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ³Ramón y Cajal University Hospital, Madrid, Spain, ⁴Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁵Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain, ⁶COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁷Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ⁸Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁹Hospital del Mar, Barcelona, Spain, ¹⁰Rheumatology. Hospital Universitario Araba., Vitoria, Pais Vasco, Spain, ¹¹Galdakao- Usansolo University Hospital, Galdakao, Spain, ¹²Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹³Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ¹⁴Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹⁵Hospital Universitario del Henares, Madrid, Spain, ¹⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁷Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Interstitial lung disease (ILD) in Rheumatoid Arthritis (RA) determines a worse prognosis with an increased mortality. Abatacept and rituximab may be the preferred therapies.…
Abstract Number: 1982 • ACR Convergence 2025
Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Kuan-Tung Lin¹, Yue Hao², Mai Abdelnabi² and Wai-Hang Jackie Lam², ¹North East Medical Services, San Mateo, CA, ²North East Medical Services, San Francisco, CA
Background/Purpose: Patients with rheumatologic conditions who are on immunosuppressive therapy face an elevated risk of pneumococcal infections, particularly those in medically underserved populations. Per ACR…
Abstract Number: 1896 • ACR Convergence 2025
Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program
Jeong Yee¹, Emily Oakes², Candace Feldman³ and Karen H. Costenbader⁴, ¹Sungkyunkwan University, Suwon, MA, South Korea, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Electronic cigarettes, or e-cigarettes, are inhalable aerosol nicotine-delivery devices increasingly used in addition or in place of cigarettes. Cigarette smoking is strongly associated with…
Abstract Number: 1732 • ACR Convergence 2025
Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis
Takemichi Matsui¹, Kenji Yamada², Toshiaki Takahashi³, Yoshito Nishimura⁴ and Yu Fujiwara⁵, ¹Department of Medicine, Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Allergy and Rheumatology, Kameda Medical Center, Chiba, Japan, ³Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, ⁴Division of Hematology/Oncology, Mayo Clinic, Rochester, MN, ⁵Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have become essential in cancer treatment, offering significant survival benefits across various malignancies. However, ICIs can cause immune-related Adverse Events…
Abstract Number: 1658 • ACR Convergence 2025
Cardiovascular Disease Risk and Risk Calculator Performance in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Omair Khan¹, Halie Frideres², Punyasha Roul³, Grant Cannon⁴, Gary Kunkel⁵, Brian Sauer⁶, Joshua Baker⁷, Ted Mikuls¹, Bryant England¹ and Tate Johnson¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Existing cardiovascular disease (CVD) risk stratification strategies underperform in RA. Lung disease is an established CVD risk factor, and RA-interstitial lung disease (RA-ILD) clinically…
Abstract Number: 1367 • ACR Convergence 2025
Molecular Signature Response Classifier Identifies Contribution of GLP-1 Therapy to TNF Inhibitor Response in Rheumatoid Arthritis Patients
Lixia Zhang¹, Angus Wong², Alex Jones², Sherry Guardiano², Reginald Seeto² and Ryan T, Phan³, ¹Scipher Medicine, Plainsboro, NJ, ²Scipher Medicine, Waltham, ³Scipher Medicine, Los Gatos
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) are extensively utilized in the management of rheumatoid arthritis (RA). Therapeutic responses remain highly heterogeneous. Emerging evidence suggests glucagon-like…
Abstract Number: 1349 • ACR Convergence 2025
Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-To-Severe Rheumatoid Arthritis in a Real-World Setting: Final 2-year Outcomes from the UPHOLD Study
Andrew Ostor¹, Eugen feist², Prodromos Sidiropoulos³, Jérôme Avouac⁴, Martin Rebella⁵, Rajaie Namas⁶, Erin McDearmon-Blondell⁷, Ivan Lagunes⁸, Tianming Gao⁹, Tim Shaw⁷ and Suzan Attar¹⁰, ¹Australian National University, Canberra, Australia, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece, ⁴Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁵Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁶Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁷AbbVie Inc., North Chicago, IL, ⁸Abbvie Inc, North Chicago, IL, ⁹AbbVie, North Chicago, IL, ¹⁰King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia
Background/Purpose: We evaluated long-term achievement of treatment targets, sustained clinical response, and safety of upadacitinib (UPA) over 2 years in patients with moderate-to-severe rheumatoid arthritis…
Abstract Number: 1332 • ACR Convergence 2025
Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases
Gilad Halpert¹, Yair Dankner², Eri Govrin¹, Abdulla Watad³, Omer Gendelman¹, Shlomo Segev¹, Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Shenkar College of Engineering and Design, Ramar Gan, Israel, ³Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: Spectral analysis of liquid biopsies has recently emerged as a promising, non-invasive approach to improve the diagnosis of various pathologies. Our objective was to…
Abstract Number: 1316 • ACR Convergence 2025
Predicting mortality of rheumatoid arthritis in China: A nation-wide cohort study
Kangping Huang¹, Shixiong Wei², Lan Zhang³, Xinhao Li², Mucong Li², Chen Yu⁴, Nan Jiang², Jiuliang Zhao², Yanhong Wang⁵, Chanyuan Wu², Peng Yin⁶, Qian Wang², Mengtao Li², Xinping Tian² and Xiaofeng Zeng⁷, ¹Peking Union Medical College, Beijing, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ³School of Public Health, Peking University, Beijing, Beijing, China (People's Republic), ⁴Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁵Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, Beijing, China (People's Republic), ⁶National Center for Chronic and NCD Control and Prevention, Chinese Center for Disease Control and Prevention, Xicheng, Beijing, China (People's Republic), ⁷Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with increased mortality, primarily due to systemic inflammation and comorbidities. While previous studies have identified…
Abstract Number: 1238 • ACR Convergence 2025
Pain Is Associated with An Increased Risk of Frailty in Veterans with Rheumatoid Arthritis
Nadine El-ayache¹, Sayuli Bhide², Hannah Brubeck³, Punyasha Roul⁴, Bryant England⁵, Joshua Baker⁶, Grant Cannon⁷, Namrata Singh⁸, Gary Kunkel⁹, Ted Mikuls⁵, Patti Katz¹⁰, Dolores Shoback¹¹, Jose Garcia¹², Pradeep Suri¹³, Marianna Gasperi¹³, Ariela Orkaby¹⁴, Una Makris¹⁵ and Katherine Wysham¹⁶, ¹VA Puget Sound Health Care System & University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³VA Puget Sound Health Care System, Seattle, WA, ⁴UNMC, Omaha, NE, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁸University of Washington, Bellevue, WA, ⁹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹⁰UCSF, San Rafael, CA, ¹¹San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ¹²VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ¹³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, ¹⁴VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA, ¹⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ¹⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty, an increased vulnerability to stressors, is commonly associated with aging and functional decline. Pain, prevalent among older adults, contributes to frailty in the…
Abstract Number: 1081 • ACR Convergence 2025
Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment
Ramsha Riaz¹, Lifang Zhang², Andrea Berger², Hema Srinivasan², Lisa Schroeder³ and Jonida Cote⁴, ¹Geisinger Medical Center, Danville, PA, ²Geisinger Health System, Danville, PA, ³Geisinger, Danville, PA, ⁴Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: Recognizing health care disparities in Rheumatoid Arthritis is crucial to improving outcomes. This study analyzes factors contributing to RA care inequities.Methods: We examined RA…
Abstract Number: 1007 • ACR Convergence 2025
Accelerometry-Derived Activity and Sleep Patterns in the NIH All of Us Cohort: Insights and Predictive Potential for Inflammatory Arthritis
adeep Kulkarni¹, Jose Scher², Rebecca Haberman³ and Souptik Barua¹, ¹New York University Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Health, New York, NY
Background/Purpose: Patients with inflammatory arthritis (IA) report reduced physical activity and poor sleep, However, much remains unknown about the extent and impact of this relationship.…
Abstract Number: 0906 • ACR Convergence 2025
Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
Yao Xiong, Shuaixiang Zhou, Zhimin Zhang, Bin Li, Zhihao Ming, Yuyu Wu, Liu Li, Chang Li, Fenggen Fu, Zhihai Wu, Shun Wang, Guogang Yuan, Yuling Song, Jinyang Li, Huizhong Xiong and Bingliang Chen, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Dysregulated B-cell activation plays a pivotal role in the pathogenesis of various autoimmune diseases. B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].